



Insmmed to Present at Two October Conferences

October 1, 2018

BRIDGEWATER, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Insmmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that management will participate in the following investor conferences:

- The Cantor Fitzgerald Global Healthcare Conference in New York City on Monday, October 1, 2018 at 4:40 p.m. ET.
- The Leerink Partners Roundtable Series: Rare Disease & Oncology in New York City on Tuesday, October 2, 2018 at 1:30 p.m. ET.

These presentations will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcasts will be archived for a period of 90 days following the conclusion of each live event.

About Insmmed

Insmmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmmed's first commercial product is ARIKAYCE[®] (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of *Mycobacterium avium* complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.

Contact:

Blaine Davis

Insmmed Incorporated

(908) 947-2841

blaine.davis@insmed.com



Source: Insmmed, Inc.